AirFluSal MDI: a new LABA/corticosteroid inhaler

AirFluSal MDI (salmeterol/fluticasone) is indicated for the regular treatment of asthma where use of a combination product containing a long-acting ß2-agonist and an inhaled corticosteroid is appropriate.

AirFluSal MDI (salmeterol/fluticasone) is available in two strengths: 25/125 microgram and 25/250 microgram.
AirFluSal MDI (salmeterol/fluticasone) is available in two strengths: 25/125 microgram and 25/250 microgram.

AirFluSal MDI can be used in patients from 18 years of age who are not adequately controlled with inhaled corticosteroids and an ‘as needed' inhaled short-acting β2-agonist, or who are already adequately controlled on both an inhaled corticosteroid and a long-acting β2-agonist. Two puffs are taken twice daily.

As AirFluSal MDI is not available in a 25/50 microgram presentation, patients requiring titration down to a dose of inhaled corticosteroid below 125 microgram must be switched to an alternative salmeterol/fluticasone inhaler.

AirFluSal MDI can be used with either the Volumatic or AeroChamber Plus spacer device.

The efficacy and safety of salmeterol and fluticasone for the treatment of asthma are well established. AirFluSal is already available as a breath-actuated dry-powder inhaler in the Forspiro device.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases